MedTrace Logo

Chemotherapy-Induced Cognitive Impairment

NCT01578083 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2013-02-26

No results posted yet for this study

Summary

The investigators overall research hypothesis is that systemic chemotherapy induces structural changes in the white matter of the brain as demonstrated with Diffusion Tensor Imaging (DTI) and functional changes in well-defined cortical neural networks as demonstrated by resting-state functional connectivity MRI (rs-fcMRI). The investigators believe these structural and functional changes are responsible for the cognitive symptoms associated with chemotherapy-induced cognitive impairment (CICI).

The Specific Aim for this study is:

To assess the impact of chemotherapy on structural white matter as defined by DTI and functional cognitive networks as defined by rs-fcMRI by comparing a sample of breast cancer survivors with self-reported CICI to breast cancer survivors without CICI.

Hypothesis: Post-chemotherapy breast cancer patients with self-reported CICI will have abnormal structural connections characterized by DTI-defined disruptions in fractional anisotropy (FA) and mean diffusivity (MD) and abnormal functional connectivity characterized by rs-fcMRI-defined disruptions in cognitive networks when compared to patients without self-reported CICI.

Conditions

  • Cognitive Symptoms

Sponsors & Collaborators

  • Washington University Siteman Cancer Center

    collaborator OTHER

  • Barnes-Jewish Hospital

    collaborator OTHER

  • Jay F. Piccirillo, MD

    lead OTHER

Principal Investigators

  • Jay F. Piccirillo, MD · Washington University School of Medicine

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01578083 on ClinicalTrials.gov